UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $22.
UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $22.